- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02108639
To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet
An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Fixed Dose Combination Formulation of DCV, ASV, and BMS-791325 in Subjects With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
IND Number: 79,599/101,943
Primary Purpose: Other - Phase 1 Clinical Pharmacology study to determine the effect of renal impairment on the exposure of DCV, ASV, BMS-791325 (fixed dosed combination) and BMS-791325 given in multiple doses
Fixed dose combination (FDC)
Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325 (DCV 3DAA FDC)
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Florida
-
Miami, Florida, Forenede Stater, 33014
- Clinical Pharmacology Of Miami Inc.
-
Orlando, Florida, Forenede Stater, 32809
- Orlando Clinical Research Center
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55404
- Davita Clinical Research
-
-
Tennessee
-
Knoxville, Tennessee, Forenede Stater, 37920
- New Orleans Center For Clinical Research - Knoxville
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Subjects in Group A must be in good health and have normal renal function
- Subjects in Groups B-E may have clinical, Electrocardiogram (ECG) and laboratory findings consistent with their degree of renal dysfunction
- Women of childbearing potential (WOCBP) and male participants must agree to follow the required contraceptive methods
Exclusion Criteria:
- Subjects in Group A must not have any significant acute or chronic illnesses
- Subjects in Groups B-E must not have uncontrolled or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, and/or neurological disease within 6 months of screening
- Subjects in Groups B-E may not have evidence of rapidly deteriorating renal function, defined as a screening creatinine clearance (CLcr) which has decreased from a previous CLcr by 50% within the last 3 months
- Prior exposure to DCV, ASV or BMS-791325 within 3 months prior to study drug administration
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: DCV 3DAA FDC + BMS-791325
Group A to D: DCV 3DAA FDC + BMS-791325 oral tablets on specific days Group E: DCV 3DAA FDC + BMS-791325 oral tablets on specific days |
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Maximum observed plasma concentration (Cmax) for DCV, ASV, BMS-791325 and BMS-794712
Tidsramme: For Groups A-D: Day 1 to Day 10 and for Group E: Day 1 to Day 12
|
For Groups A-D: Day 1 to Day 10 and for Group E: Day 1 to Day 12
|
Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) for DCV, ASV, BMS-791325 and BMS-794712
Tidsramme: For Groups A-D: Day 1 to Day 10 and for Group E: Day 1 to Day 12
|
For Groups A-D: Day 1 to Day 10 and for Group E: Day 1 to Day 12
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Concentration at 12 hours (C12) for (DCV, ASV, BMS-791325) and BMS-948158
Tidsramme: For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
|
Time of maximum observed concentration (Tmax) for (DCV, ASV, BMS-791325) and BMS-948158
Tidsramme: For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
|
Apparent total body clearance (CLT/F) for (DCV, ASV and BMS-791325 only)
Tidsramme: For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
|
Trough observed plasma concentration (Ctrough) for (DCV, ASV, BMS-791325), BMS-794712 and BMS-948158
Tidsramme: For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
|
Cmax fraction unbound (Cmaxfu) for (DCV, ASV, BMS-791325), BMS-794712 and BMS-948158
Tidsramme: For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
BMS-948158 may also be analyzed
|
For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
AUC(TAU) fraction unbound (AUC(TAU) fu) for (DCV, ASV, BMS-791325), BMS-794712 and BMS-948158
Tidsramme: For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
BMS-948158 may also be analyzed
|
For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
Protein Binding for DCV, ASV, BMS-791325 and BMS-794712
Tidsramme: 1 and 4 hours postdose on Day 10 (all subjects) and Day 12 (Group E only)
|
1 and 4 hours postdose on Day 10 (all subjects) and Day 12 (Group E only)
|
|
Total amount recovered in urine (URt) for (DCV, ASV, BMS-791325) and BMS-794712
Tidsramme: For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
|
Total percent of administered dose recovered in urine (%URt) for (DCV, ASV, and BMS-791325 only)
Tidsramme: For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
|
Renal clearance (CLR) for DCV, ASV, BMS-791325, and BMS-794712
Tidsramme: For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
|
Maximum observed concentration (Cmax) for BMS-948158
Tidsramme: For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
|
Area under the concentration-time curve in 1 dosing interval (AUC (TAU)) for BMS-948158
Tidsramme: For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
|
Safety based on occurrence of Adverse Event (AEs), Serious adverse event (SAEs) and AEs leading to discontinuation
Tidsramme: For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
|
Safety based on abnormalities in vital sign measurements
Tidsramme: For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
|
Safety based on findings on ECG measurements and physical examinations
Tidsramme: For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
|
Safety based on Marked abnormalities in clinical laboratory test findings
Tidsramme: For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Leversygdomme
- Flaviviridae infektioner
- Hepatitis, viral, menneskelig
- Hepatitis
- Hepatitis C
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Proteasehæmmere
- Asunaprevir
Andre undersøgelses-id-numre
- AI443-110
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hepatitis C
-
Tripep ABInovio PharmaceuticalsUkendtKronisk hepatitis C virusinfektionSverige
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsTrukket tilbageKronisk hepatitis C virusinfektionIsrael
-
Hadassah Medical OrganizationUkendtKronisk hepatitis C virusinfektionIsrael
-
Beni-Suef UniversityAfsluttetKronisk hepatitis C virusinfektionEgypten
-
Trek Therapeutics, PBCAfsluttetKronisk hepatitis C | Hepatitis C genotype 1 | Hepatitis C (HCV) | Hepatitis C viral infektionForenede Stater, New Zealand
-
Trek Therapeutics, PBCAfsluttetKronisk hepatitis C | Hepatitis C (HCV) | Hepatitis C genotype 4 | Hepatitis C viral infektionForenede Stater
-
AbbVieAfsluttetKronisk hepatitis C | Hepatitis C (HCV) | Hepatitis C genotype 1a
-
AbbVie (prior sponsor, Abbott)AfsluttetKronisk hepatitis C | Hepatitis C genotype 1 | Hepatitis C (HCV)Forenede Stater, Australien, Canada, Frankrig, Tyskland, New Zealand, Puerto Rico, Spanien, Det Forenede Kongerige
-
Humanity and Health Research CentreBeijing 302 HospitalAfsluttetKronisk hepatitis C-infektionKina
-
PharmaEssentiaAfsluttetKronisk hepatitis C virusinfektionKorea, Republikken, Taiwan, Kina
Kliniske forsøg med DCV 3DAA FDC
-
Bristol-Myers SquibbAfsluttetHepatitis CForenede Stater
-
Bristol-Myers SquibbAfsluttet
-
Bristol-Myers SquibbAfsluttetHepatitis C infektion
-
Bristol-Myers SquibbAfsluttet
-
Bristol-Myers SquibbAfsluttet
-
Timothy Morgan, MDBristol-Myers Squibb; National Cancer Institute (NCI); VA Long Beach Healthcare...Afsluttet
-
Humanity & Health Medical Group LimitedTrukket tilbage
-
Bristol-Myers SquibbAfsluttetHepatitis C virusKorea, Republikken, Taiwan, Den Russiske Føderation
-
ViiV HealthcareGlaxoSmithKlineAfsluttetInfektion, Human Immundefekt VirusForenede Stater
-
Humanity and Health Research CentreUniversity of Maryland; Emory University; Beijing 302 HospitalTrukket tilbageKronisk hepatitis C-infektionHong Kong